The notices it replaced
- Reissues: PAR-14-269 Innovative Therapies and Tools for Screenable Disorders in Newborns (R21)
- 2 steps back: PAR-10-232 Innovative Therapies and Tools for Screenable Disorders in Newborns (R21)
- 3 steps back: PAR-06-059
Replaced by PAR-21-355.
Who won it before
11 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,636,951 in first-year total cost, median $239,250.
Most frequent study sections
- Therapeutic Approaches to Genetic Diseases Study Section[TAG]7
- Special Emphasis Panel[ZRG1 GGG-A (50)]2
- Special Emphasis Panel[ZRG1 GGG-B (50)]2
Most frequent institutions
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI3
- CHILDREN'S RESEARCH INSTITUTE1
- CINCINNATI CHILDRENS HOSP MED CTR1
- STATE UNIVERSITY OF NEW YORK AT BUFFALO1
- TUFTS UNIVERSITY MEDFORD1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Developing Synthetic Enzymes to Treat Inborn Errors of Metabolism1R21HD105934-01 | NAIR, NIKHIL UNNI | TUFTS UNIVERSITY MEDFORD, MA | $190,711 | TAG |
| 2021 | Substrate reduction as a novel therapeutic strategy for Glutaric Aciduria Type 11R21HD102745-01A1 | DEVITA, ROBERT JHOUTEN, SANDER MICHEL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $296,407 | TAG |
| 2021 | Identification of biomarkers for biochemical, pathophysiological and neurological effects of high ammonia concentration on the central nervous system in a preclinical model of neonatal hyperammonemia1R21HD099329-01A1 | AH MEW, NICHOLASCALDOVIC, LJUBICA MORIZONO | CHILDREN'S RESEARCH INSTITUTE, DC | $267,750 | TAG |
| 2021 | Advancing a novel experimental mRNA-based therapy for Classic Galactosemia1R21HD104056-01A1 | LAI, KENT | UNIVERSITY OF UTAH, UT | $228,750 | TAG |
| 2021 | Biochemical and Molecular Newborn Screening for Familial Hypercholesterolemia1R21HD102793-01A1 | PETERSON, AMY LH | UNIVERSITY OF WISCONSIN-MADISON, WI | $155,417 | TAG |
| 2020 | Brain organoid modeling of Gaucher disease for identification of pathogenic pathways and therapy development1R21HD102788-01 | SUN, YING | CINCINNATI CHILDRENS HOSP MED CTR, OH | $238,500 | TAG |
| 2019 | Improving Critical Congenital Heart Disease Screening and Detection of "Secondary" Targets1R21HD099239-01 | SIEFKES, HEATHER M | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $240,804 | TAG |
| 2018 | T cell-mediated Gene Replacement Therapy1R21HD091461-01A1 · under PAR-14-269 | BROWN, BRIAN D | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $251,737 | ZRG1 |
| 2018 | Surfactant Protein-A as a biomarker to predict development of NEC in infants1R21HD094069-01 · under PAR-14-269 | ALCORN, JOSEPH L | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $231,000 | ZRG1 |
| 2017 | Novel Treatment Options for Glutaric Aciduria1R21HD088775-01A1 · under PAR-14-269 | DEVITA, ROBERT JHOUTEN, SANDER MICHEL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $296,625 | ZRG1 |
| 2016 | Enhancement Newborn Screening to Improve the Efficacy of Cord Blood Transplant for Krabbe Disease1R21HD087818-01 · under PAR-14-269 | CARTER, RANDOLPH LEELANGAN, THOMAS J | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $239,250 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.